Process Development Scientist

About Us

Eupraxia is a clinical‑stage biotechnology company focused on developing locally delivered, extended‑release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer‑based micro‑sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology supports an extended duration of effect and delivery of drugs in a hyper‑localized fashion, targeting only the tissues that physicians want to treat. By achieving precision targeting and stable, flat delivery of the active ingredient, DiffuSphere™ may reduce adverse events compared with traditional drug delivery methods. This platform has the potential to augment and transform FDA‑approved drugs, improving safety, tolerability, efficacy and duration of effect. Eupraxia is currently developing treatments beyond pain and inflammatory gastrointestinal disease—including oncology, infectious disease ...